Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma by Wick, W et al.
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2010
Phase III study of enzastaurin compared with lomustine in the
treatment of recurrent intracranial glioblastoma
Wick, W; Puduvalli, V K; Chamberlain, M C; van den Bent, M J; Carpentier, A F;
Cher, L M; Mason, W; Weller, M; Hong, S; Musib, L; Liepa, A M; Thornton, D E;
Fine, H A
Wick, W; Puduvalli, V K; Chamberlain, M C; van den Bent, M J; Carpentier, A F; Cher, L M; Mason, W; Weller,
M; Hong, S; Musib, L; Liepa, A M; Thornton, D E; Fine, H A (2010). Phase III study of enzastaurin compared with
lomustine in the treatment of recurrent intracranial glioblastoma. Journal of Clinical Oncology, 28(7):1168-1174.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Journal of Clinical Oncology 2010, 28(7):1168-1174.
Wick, W; Puduvalli, V K; Chamberlain, M C; van den Bent, M J; Carpentier, A F; Cher, L M; Mason, W; Weller,
M; Hong, S; Musib, L; Liepa, A M; Thornton, D E; Fine, H A (2010). Phase III study of enzastaurin compared with
lomustine in the treatment of recurrent intracranial glioblastoma. Journal of Clinical Oncology, 28(7):1168-1174.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Journal of Clinical Oncology 2010, 28(7):1168-1174.
Enzastaurin versus lomustine in the treatment of recurrent intracranial 
glioblastoma: A phase III study 
Wolfgang Wick1*, Vinay K. Puduvalli2, Marc Chamberlain3†, Martin van den Bent4, 
Antoine F. Carpentier5, Lawrence M. Cher6, Warren Mason7, Michael Weller7‡, 
Shengyan Hong8, Luna Musib8, Astra M. Liepa8, Donald E. Thornton8, Howard A. Fine9 
1University of Tübingen Medical School, Tübingen, Germany; 2University of Texas, M. 
D. Anderson Cancer Center, Houston, TX, USA; 3H. Lee Moffitt Cancer Center, Tampa, 
FL, USA; 4Erasmus Medisch Centrum, Rotterdam, Netherlands; 5Hopital Pitie 
Salpetriere, Paris, France; 6Austin Health, Victoria, Australia; 7Princess Margaret 
Hospital and the University of Toronto, Toronto, Ontario, Canada; 8Eli Lilly and 
Company, Indianapolis, IN, USA; 9Neuro-Oncology Branch, National Cancer Institute, 
Bethesda, MD, USA 
Research support: The study was sponsored by Eli Lilly and Company. 
Corresponding author: Wolfgang Wick, MD, Department of Neurooncology, University 
of Heidelberg, Im Neuenheimer Feld, 400 D-69120 Heidelberg. Telephone: + 49 (0) 
6221/56-7075; Fax: + 49 (0) 6221/56-7554; e-mail: wolfgang.wick@med.uni-
heidelberg.de 
 2
Running title: Phase III study of enzastaurin in glioblastoma 
This article is an original report that was presented in part at the 44th American Society 
of Clinical Oncology Annual Meeting, Chicago, IL, May 30-June 3, 2008. 
*Current affiliation: Department of Neurooncology, University of Heidelberg, Germany. 
†Current affiliation: University of Washington, Fred Hutchinson Cancer Research 
Center, Seattle Cancer Care Alliance, Seattle, WA, USA. 
‡Current affiliation: Department of Neurology, University Hospital Zurich, Zurich, 
Switzerland. 
 3
ABSTRACT 
Purpose: This phase III open-label study compared the efficacy and safety of enzastaurin 
versus lomustine in patients with recurrent glioblastoma (WHO grade IV). 
Patients and Methods: Patients were randomized 2:1 to receive 6-week cycles of 
enzastaurin 500 mg/day (1125-mg loading dose, day 1) or lomustine (100–130 mg/m2, 
day 1). Assuming a 45% improvement in progression-free survival (PFS), 397 patients 
were required to provide 80% power to achieve statistical significance at a one-sided 
level of 0.025. 
Results: Enrollment was terminated at 266 patients (enzastaurin=174; lomustine=92) 
after a planned interim analysis for futility. Patient characteristics were balanced between 
arms. Median PFS [1.5 vs 1.6 months, HR=1.28 (95% CI: 0.97, 1.70)], overall survival 
(OS) [6.6 vs 7.1 months, HR=1.20 (95% CI: 0.88, 1.65)], and 6-month PFS rate (P=0.13) 
did not differ significantly between enzastaurin and lomustine, respectively. Stable 
disease occurred in 38.5% and 35.9% of patients and objective response in 2.9% and 
4.3% of patients, respectively. Time to deterioration of physical and functional well-
being and symptoms did not differ between arms (HR=1.12; P=0.54). Four patients 
discontinued enzastaurin due to drug-related serious adverse events (SAEs). Eleven 
patients on enzastaurin died on-study (4 due to AEs: 1 drug-related). All 4 deaths on 
lomustine were disease-related. Grade 3/4 hematological toxicities were significantly 
higher on lomustine (46 events) than on enzastaurin (1 event) (P ≤0.001).  
Conclusion: Enzastaurin was well tolerated and had a better hematological toxicity 
profile but did not have superior efficacy compared with lomustine in patients with 
recurrent glioblastoma. 
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INTRODUCTION 
Treatment of glioblastoma, a highly lethal brain tumor,1,2 includes maximal surgical 
resection followed by radiotherapy and adjuvant chemotherapy3-5 and, recently, 
temozolomide.6 Regardless of initial treatment, all patients relapse. 
There is no standard systemic therapy available for recurrent glioblastoma, although 
nitrosoureas are most commonly used at recurrence.7 Salvage chemotherapies 
infrequently result in radiographic and/or clinical improvement, and have a limited 
impact on overall survival (OS).8-10 In patients who relapse following temozolomide, 
response rates (RR) are low and only a limited number of non-alkylating agents are 
available.11 Clearly, active well-tolerated agents that target the underlying molecular 
abnormalities in gliomas and do not have cross-resistance with alkylating agents are 
needed.  
Gliomas are highly vascular tumors and the degree of vascularity is associated with 
malignant progression.12, 13 Tumor grade and poor prognosis correlate with vascular 
endothelial growth factor (VEGF) expression.14 VEGF-induced angiogenesis is mediated 
by PKC,15, 16 while uncontrolled cell growth and chemoresistance are commonly 
attributed to PTEN loss and PI3K/AKT pathway activation.17-19 Thus, agents that target 
angiogenesis and other tumor-dependent signaling pathways are potentially of interest for 
the treatment of malignant gliomas.20-22 
Enzastaurin, an oral serine/threonine kinase inhibitor, targets both the PKC and the 
PI3K/AKT pathways23 to induce apoptosis and suppress proliferation and tumor-induced 
angiogenesis, as demonstrated in various preclinical models including U87MG glioma 
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cell lines and mouse xenografts.23-25 In clinical studies, enzastaurin is well tolerated and 
has shown encouraging activity in a variety of tumors.26, 27 In a phase II study of 
enzastaurin in heavily pretreated patients with recurrent glioblastoma, an interim analysis 
showed an objective radiographic RR of approximately 20%.28 
Based on these encouraging interim data, a randomized phase III study was initiated to 
compare the efficacy of enzastaurin versus lomustine in recurrent glioblastoma. 
Lomustine was used as the comparator since nitrosoureas have been most commonly 
used at recurrence and because an oral agent was preferred.7 The primary objective was 
to compare progression-free survival (PFS). Secondary objectives included comparison 
of OS, objective response, safety, and patient-reported outcomes. Because this trial was 
based on results from the interim analysis of a single-site phase II trial,28 an interim 
analysis was planned to determine if it was scientifically and ethically appropriate to 
continue enrollment. 
PATIENTS AND METHODS 
Eligibility Criteria 
Inclusion criteria: 18 years of age; life expectancy 8 weeks; Karnofsky performance 
status (KPS) 70; histologically confirmed WHO grade IV glioblastoma (including 
gliosarcomas); magnetic resonance imaging (MRI) evidence of tumor progression 
following radiation and chemotherapy (12 weeks must have elapsed since completion of 
radiotherapy or 4 weeks for chemotherapy); ≤2 prior chemotherapy regimens; recovery 
from initial surgery; and adequate organ function. Enzyme-inducing antiepileptic drugs 
(EIAEDs) were to be discontinued 14 days before study enrollment. 
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Exclusion criteria: prior enzastaurin therapy within 30 days of enrollment; treatment with 
any nitrosourea (including lomustine), bevacizumab, investigational drugs, or 
intratumoral chemotherapy; stereotactic radiosurgery; concurrent systemic anticancer 
therapy or anticoagulant therapy; second primary malignancy; serious concomitant 
systemic disorders; electrocardiogram or other clinically significant cardiac 
abnormalities; and pregnancy or breastfeeding. 
All patients signed a consent form approved by the participating institution’s ethical 
review board. The study was conducted in accordance with the Declaration of Helsinki 
and good clinical practices. 
Study Design and Treatment Plan 
In this phase III, multicenter, open-label study, patients were randomized 2:1 to receive 
500 mg oral enzastaurin daily (1125-mg loading dose on day 1) or 100 to 130 mg/m2 
lomustine on day 1. A 6-week cycle was chosen because the nadir of lomustine at this 
dose occurs between days 30 and 35. Randomization factors included age, first or second 
recurrence, and KPS. Treatment continued until disease progression or unacceptable 
toxicity occurred. 
Enzastaurin was omitted for an absolute neutrophil count (ANC) <0.5 × 109/L for longer 
than 7 days, an ANC <1.0 × 109/L with fever (temperature of 101°F/38.5°C), or a platelet 
count <25 × 109/L; grade ≥3 transaminase elevations; or grade ≥3 clinically relevant non-
hematological toxicities. If an event resolved to grade ≤1 or patient’s baseline, treatment 
was resumed at 250 mg/day and re-escalated to 375 mg/day if the event did not recur for 
21 days. 
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Lomustine was discontinued if treatment could not be administered for 21 days from the 
time of the next scheduled treatment or if a patient with two prior dose reductions 
experienced a toxicity that caused a third dose reduction. The dose was reduced by 30% 
for an ANC of 1.0–1.5 × 109/L or platelets 25–74.9 × 109/L, and by 50% for an ANC 
<1.0 × 109/L or platelets <25 × 109/L. Lomustine was restarted after hematological 
toxicities resolved to baseline. Lomustine was delayed for grade ≥3 non-hematological 
toxicity until resolution to baseline and reduced by 50% for clinically relevant toxicities. 
The full dose was resumed if the event did not recur for 42 days after restarting therapy.  
Baseline and Treatment Assessments 
Tumor evaluations and neuroradiologic exams using MRI were done after every cycle ( 
5 days). Steroid doses had to be stable for 5 days preceding the MRI. All randomized 
patients (intent-to-treat) were evaluated for efficacy using modified Levin’s criteria.29 
Neuroradiologic data were independently reviewed (central review) to confirm response 
and progression. Objective response was confirmed by a second MRI >4 weeks after the 
first evidence of response. Subsequent MRI was collected every 6 weeks until 
progressive disease (PD). Patients had stable disease if no meaningful change was noted 
in the post-contrast T1 images. PD was defined as increased extent of the enhancing 
component of evaluable lesions compared to the nadir time point, the appearance of any 
new lesion, or the worsening of neurologic symptoms. 
Patients, who discontinued because of PD were evaluated as clinically indicated; those 
without PD were evaluated every 42 days (±5 days) until progression or initiation of a 
new treatment. 
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Patients who received ≥1 dose of study drug were evaluated for safety using Common 
Terminology Criteria for Adverse Events (CTCAE) v3.0. 
Patients completed the 50-item Functional Assessment of Cancer Therapy-Brain (FACT-
Br, version 4)30, 31 before randomization, every 3 weeks, and after discontinuation. 
Patients with baseline and ≥1 post-baseline assessment were included in the analysis of 
time to deterioration (TtD), measured from the date of randomization to the first date of 
deterioration in the Trial Outcome Index (TOI; physical and functional well-being plus 
brain tumor-specific concerns) or death. Deterioration was defined as a decrease from 
baseline in the TOI that was at least the minimally important difference (11-point 
decrease on the 148-point TOI scale).  
Statistical Methods 
Planned enrollment was 397 patients using a Pocock-Simon minimization algorithm. The 
baseline factors used in minimization included age (<50 vs ≥50), KPS (≤80/>80), disease 
recurrence (yes/no), and institution. The final analysis was planned after 256 PFS events 
(progression or death), which provided 80% power to achieve statistical significance at a 
one-sided level of 0.025, assuming a 45% improvement in median PFS of enzastaurin 
over lomustine.  
Survival was determined using Kaplan-Meier estimates and was compared between arms 
using the log-rank test. The Cox model was used to estimate the hazard ratio (HR), with 
treatment as the only covariate, and to assess treatment-by-factor interaction for each pre-
specified baseline factor. 
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One interim analysis was planned after 107 PFS events to evaluate safety and futility. 
The futility bound was determined by simulations using a conditional power approach; as 
guidance, the study would be considered futile if the conditional power under the 
alternative hypothesis (a 45% improvement in median PFS) was <31%. Although this 
was an open-label study, the sponsor was blinded to the aggregate database. Only an 
independent data monitoring committee (DMC) had access to the unblinded data.  
Pharmacokinetic Assessments 
Plasma samples were collected from patients in the enzastaurin arm on day 1 (1 to 5 
hours after the first dose of the loading dose) and day 21 of cycle 1 (pre-dose and 3 to 8 
hours post-dose), or at the time of discontinuation if before day 21 of cycle 1. If a patient 
continued on-study for ≥4 cycles, an additional plasma sample was collected pre-dose on 
day 1 of cycle 4. Pharmacokinetic analyses for enzastaurin and its metabolites were done 
at Advion BioServices, Inc. (Ithaca, NY, USA) using the validated liquid 
chromatography and tandem mass spectrometry method. 
RESULTS 
Patient Characteristics 
From March 2006 to August 2007, 293 patients entered at 76 sites in 14 countries and 
266 were deemed eligible and randomized (Figure 1). Enrollment was stopped at the 
recommendation of the DMC after the interim analysis for futility, which was conducted 
after 115 (43%) enrolled patients had PD or died. 
Patient characteristics were balanced between the two arms (Table 1). The differences 
observed between arms for gender and age were not statistically significant (P=0.35 and 
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P=0.39, respectively). The median time from initial diagnosis to randomization was 
numerically longer in the lomustine arm (10.1 versus 12.1 months).  
Study Drug Administration 
The median duration of therapy for enzastaurin was 42 days (range, 0–330+ days). The 
mean daily dose for enzastaurin was 513.09 mg (102.6% of the planned daily dose), 
excluding the loading dose. Three patients continued to receive enzastaurin for ≥1 year. 
There were two enzastaurin dose reductions due to cough and thrombocytopenia and six 
dose omissions (one each for convulsion, edema, nausea, pulmonary embolism, 
somnolence, and urinary tract infection). Twelve patients discontinued in the enzastaurin 
arm due to adverse events (AEs), four of which were possibly drug-related serious AEs 
(erysipelas, aortic thrombosis, cerebral hemorrhage, and seizure). 
Patients received a median of 1 cycle of lomustine (range, 1–8 cycles). The mean cycle 
dose for lomustine was 106.66 mg/m2 (94.9% of the planned cycle dose). There were 21 
dose reductions (11 thrombocytopenia, 7 neutropenia) and 31 dose delays, mostly due to 
scheduling conflicts (n=16) and thrombocytopenia (n=10). Four patients discontinued 
lomustine due to drug-related neutropenia, thrombocytopenia, increased transaminase, 
and non–drug-related deep vein thrombosis (1 patient each). 
Efficacy 
As shown in Figure 2a, no significant difference was seen between median PFS of 
enzastaurin (1.5 months) and lomustine (1.6 months, P=0.08; HR=1.28 [95% CI: 0.97, 
1.70]) with 10.3% and 23.9% patients censored, respectively. The 6-month PFS rate was 
11.1% for enzastaurin and 19.0% for lomustine (P=0.13). The median OS of enzastaurin 
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(6.6 months, 30.5% censoring) and lomustine (7.1 months, 35.9% censoring) was not 
significantly different (P=0.25; HR=1.20 [95% CI: 0.88, 1.65]) (Figure 2b). The median 
follow-up time for surviving patients was 8.7 months. 
Patients with a high KPS (90-100) had better PFS (2.8 months versus 1.5 months; 
P=0.007) and longer OS (10.3 months versus 7.4 months; P=0.020) with lomustine. None 
of the other baseline randomiztion factors had a significant effect on overall efficacy. 
Treatment interaction with time from initial diagnosis to randomization was not 
significant for either PFS (P=0.40) or OS (P=0.81). There was no significant difference 
in objective response (P=0.501) (Table 2).  
The consistency rate in the determination of PD between investigator and independent 
review of scans from 220 patients was 86% and did not impact the PFS analysis 
(HR=1.30 [95% CI: 0.98, 1.73]). Scans from 50 patients were also assessed by 
Macdonald’s criteria. Consistency rates were 77.5% and 70% in the enzastaurin and 
lomustine arms, respectively.  
Patient-reported Outcomes 
On-study compliance for completion of the FACT-Br was 76.7% in the enzastaurin arm 
and 78.3% in the lomustine arm.32 TtD analysis was based on 159 (91.4%) enzastaurin 
patients and 82 (89.1%) lomustine patients. Baseline scores for the TOI were not 
statistically different between arms (P=0.64) with physical well-being scores of 21.4 and 
21.3 (of 28), functional well-being scores of 15.5 and 15.4 (of 28), and brain tumor-
specific concern scores of 59.8 and 59.1 (of 92), respectively, for enzastaurin and 
lomustine. Median TtD in patients who had a baseline TOI assessment was 2.27 months 
for enzastaurin and 2.33 months for lomustine, with 6-month deterioration rates of 18% 
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and 29%, respectively (P=0.54; HR=1.12 [95% CI: 0.77, 1.63]; 47% censoring).32 The 
Pearson correlation coefficient33 of TtD with PFS was 0.42 and Kendall’s Tau was 
P=0.001. The changes from baseline for physical and functional well-being and for brain 
tumor-specific concerns were not significantly different between arms (P >0.05), with 
physical and functional well-being and brain tumor-specific concern scores worsening by 
2.5 each, over 4 cycles. 
Safety 
Fifteen patients (7 enzastaurin and 8 lomustine) discontinued before receiving treatment 
and were not included in the safety analysis (Table 3). The incidence of AEs was similar 
in both arms; however, 62% of events in lomustine were drug-related versus 44% in 
enzastaurin (P=0.008). The most common AEs observed were headache in 34 patients 
(20.4%), convulsion in 25 patients (15.0%), and fatigue in 29 patients (17.4%) in the 
enzastaurin arm and thrombocytopenia in 37 patients (44.0%), fatigue in 20 patients 
(23.8%), and nausea in 19 patients (22.6%) in the lomustine arm.  
Hematological toxicities were significantly higher with lomustine than with enzastaurin 
(P ≤0.001), including drug-related grade 3/4 thrombocytopenia, neutropenia, and 
leukopenia (P ≤0.007). Thrombocytopenia (n=1) was the only grade 3/4 hematological 
toxicity on enzastaurin. 
Significantly more patients on lomustine received transfusions (11.9% versus 0.6%; P 
<0.001). There was no difference in the number of patients hospitalized (P ≥0.247). 
Eleven (6.6%) patients on enzastaurin died on-study: 4 due to AEs, 1 due to drug-related 
cerebral hemorrhage. Within 30 days of discontinuation, 20 patients on enzastaurin died 
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due to PD and 3 due to AEs, 1 due to drug-related cerebral hemorrhage. In the lomustine 
arm, all 4 (4.8%) deaths on-study were disease-related. Eleven patients on lomustine died 
within 30 days of discontinuation (10 due to PD, 1 due to AE). 
Post-discontinuation Therapy 
Of the 70 patients on enzastaurin who received further salvage treatment, ≥5% of patients 
received lomustine (12.1%), bevacizumab (9.8%), irinotecan (9.1%), and carmustine 
(5.7%). Of the 40 patients on lomustine who received salvage treatment, ≥5% of patients 
received carboplatin (9.8%), temozolomide (9.8%), irinotecan (6.5%), lomustine (5.4%), 
etoposide (5.4%), and bevacizumab (5.4%).  
Pharmacokinetics 
Enzastaurin plasma concentration data were available from 115 patients on day 21 of 
cycle 1 and from 11 patients on day 1 of cycle 4. Steady-state plasma concentrations of 
enzastaurin and its metabolite LY326020 were within the range seen previously in 
patients with solid tumors.26 
DISCUSSION 
This is the first phase III trial evaluating a targeted therapeutic agent for the treatment of 
recurrent glioblastoma. The interim analysis served to determine whether enzastaurin was 
superior to lomustine and if it was appropriate to continue enrollment. Since enzastaurin 
did not demonstrate superior PFS, enrollment was stopped. The final analysis showed no 
significant difference in any of the efficacy endpoints. 
PFS was selected as the primary endpoint because previous studies indicated that the 6-
month PFS rate was an appropriate endpoint for recurrent disease.34 PFS observed in the 
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present study was similar to data obtained from other studies of targeted agents in 
recurrent glioblastoma,35-37 with the exception of other antiangiogenic targeted therapies, 
in particular, bevacizumab.20, 38, 39 However, in contrast to cediranib and bevacizumab, 
the anti-VEGF effects attributed to enzastaurin15 were not seen in this trial. Also, the 
overall response was lower. 
Given the challenge of measuring progression in recurrent glioblastoma, we used 
modified Levin response criteria,29 as in the phase II study.28, 40 Response in gliomas is 
commonly assessed using Macdonald criteria41, a derivative of the Levin criteria; 
however, there has never been a formal comparison between the two. Most recently, 
Levin criteria has been shown to be more predictive for response to antiangiogenic 
treatments than Macdonald criteria.42 Many patients with recurrent glioblastoma have 
lesions without clearly defined margins or have a cystic component and are therefore not 
amenable to bidirectional measurement. In this study, progression of such lesions was 
defined as an increase in the enhancing component on MRI, as determined by the 
institutional radiologist. An independent review of the scans from a subset of patients, 
using both study criteria and Macdonald criteria, did not show a difference in PFS. 
Furthermore, deterioration in patient-reported outcomes was consistent with PFS. 
Baseline characteristics were balanced between treatment arms. There was no significant 
treatment interaction between age or time from diagnosis to randomization and either 
PFS or OS.  
In this study, enzastaurin was well tolerated. The most common AEs observed in the 
enzastaurin arm, such as fatigue and headache, are expected in patients with 
glioblastoma. It is important to note that patients in this trial were switched from EIAEDs 
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to non-EIAEDs 14 days before the trial, which may explain the relatively high number of 
convulsions observed. Although more patients in the enzastaurin arm discontinued due to 
AEs, there were no significant differences in the incidence of SAEs, except for 
neutropenia, which occurred in significantly fewer patients in the enzastaurin arm. 
Thrombocytopenia in one patient was the only grade 3/4 toxicity observed with 
enzastaurin. This incidence of thrombocytopenia was lower than that observed in the 
earlier phase II trial.40 
In retrospect, the enthusiasm over data from the phase II trial28 led to the immediate 
initiation of this phase III trial. Although the final analysis of the phase II trial continued 
to show a relatively high ORR of 26% for recurrent glioblastoma, the overall outcome of 
patients was poor, with a median PFS of 1.3 months, a 6- month PFS rate of 7%, and a 
median OS of 4.4 months.40 The properly controlled phase III trial reported here did not 
produce an ORR similar to the phase II trial, however, both had similarly disappointing 
long-term outcomes. 
To date, clinical trials with single-agent targeted therapies have been largely 
disappointing. Bevacizumab has demonstrated a high objective response rate (according 
to the Macdonald or Levin criteria), clinical benefit, and a meaningful PFS;38, 42 however, 
the drug has not yet been tested in a controlled setting against another compound. On the 
other hand, whereas PFS was longer with single-agent bevacizumab compared to our 
trial, median OS was comparable (31 weeks).42 Given the heterogeneity of glioblastomas, 
well-controlled phase III trials will be required to conclusively demonstrate that any 
given treatment agent will provide a substantial survival benefit in recurrent 
glioblastoma. Combinatorial targeted therapy is likely to prove more successful than 
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single-agent therapy.43 The low toxicity observed with enzastaurin and the modest 
efficacy in the present trial, combined with robust preclinical data,23, 44 suggest that 
enzastaurin may be suitable for combination therapy. Clinical trials of combinations of 
enzastaurin with radiotherapy, temozolomide, carboplatin, and bevacizumab are 
ongoing.44, 45 
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Table 1. Patient Characteristics (N=266) 
 
 
Enzastaurin 
(N=174) 
Lomustine 
(N=92) 
Sex, n (%)   
Male 116 (66.7) 56 (60.9) 
Female   58 (33.3) 36 (39.1) 
Age, n (%)   
<50 years   44 (25.3) 28 (30.4) 
>50 years 130 (74.7) 64 (69.6) 
Karnofsky performance status, n (%)*   
Low (70 or 80) 83 (47.7) 46 (50.0) 
High (90 or 100) 90 (51.7) 45 (48.9) 
Pathological diagnosis, n (%)*   
Glioblastoma 171 (98.8) 89 (97.8) 
Gliosarcoma   2 (1.2) 2 (2.2) 
Median time from diagnosis to randomization 
(range), months 
10.1 (0.9, 51.5) 12.1 (4.4, 92.0) 
Disease recurrence†, n (%)    
First 129 (74.1) 70 (76.9) 
Second   45 (25.9) 21 (23.1) 
History of seizures, n (%)   
Yes   84 (48.3) 45 (48.9) 
No   90 (51.7) 47 (51.1) 
Prior therapies, n (%)   
Surgery  174 (100) 91 (98.9) 
Radiotherapy 174 (100) 91 (98.9) 
Systemic therapy   173 (99.4) 90 (97.8) 
Steroid    92 (52.9) 48 (52.2) 
EIAED therapy     54 (31.0) 25 (27.2) 
*The status of two patients was unknown. 
†Disease recurrence was reported in 91 patients in lomustine arm. 
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EIAED=enzyme inducing anti-epileptic drugs. 
 26
Table 2. Response 
Overall radiologic 
response* 
Enzastaurin 
(N=174) 
 
Lomustine 
(N=92) 
Fisher’s exact P† 
Objective response, n (%) 5 (2.9) 4 (4.3) 0.501 
Stable disease 67 (38.5) 33 (35.9) 0.692 
Progressive disease 72 (41.4) 38 (41.3) 1.000 
Unknown 30 (17.2) 17 (18.5) 0.866 
Duration of response‡, months 
Range 4.14–9.63 2.79–9.62 -- 
*Objective response was defined as decreased or no enhancement on the post-contrast T1 
images and stability or improvement on FLAIR/T2 images. 
†Comparison between regimens was based on unadjusted normal distribution 
approximation using the Fisher’s exact test. 
‡Duration of response was measured from the date when the criteria were first met for 
response until the first date of PD or death from any cause, whichever occurred first. 
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Table 3. Drug-related Toxicities* 
Enzastaurin (N=167)† Lomustine (N=84)†  
Gr 2, n (%) Gr 3/4, n (%) Gr 2, n (%) Gr 3/4, n (%) 
Non-hematological toxicities 
Fatigue 5 (3.0) 6 (3.6) 5 (6.0) 0 
Anorexia 2 (1.2) 0 0 0 
Nausea 1 (0.6) 0 2 (2.4) 0 
GI 2 (1.2) 0 0 0 
Flatulence 2 (1.2) 0 0 0 
Edema 7 (4.2) 2 (1.2) 2 (2.4) 0 
Infection 1 (0.6) 2 (1.2) 1 (1.2) 3 (3.6) 
Stomatitis 2 (1.2) 0 2 (2.4) 0 
Thrombosis 1 (0.6)   3 (1.8)‡ 0 0 
Hematological toxicities 
Anemia 1 (0.6) 0 3 (3.6) 2 (2.4) 
Neutropenia 1 (0.6) 0 4 (4.8) 17 (20.2) 
Thrombocytopenia 4 (2.4) 1 (0.6)   9 (10.7) 21 (25.0) 
Lymphopenia 0 0 2 (2.4) 0 
Leukopenia 2 (1.2) 0 3 (3.6) 6 (7.1) 
* Grade 2 or grade 3/4 toxicities in ≥1 patient in either arm. 
†15 patients (7 enzastaurin, 8 lomustine) discontinued before receiving treatment and 
were not included in the safety analysis. 
‡Two patients on enzastaurin had grade 4 thrombosis. 
Gr=grade; GI=gastrointestinal. 
 28
Figure Legends 
Figure 1. CONSORT flowchart. 
Figure 2a. Progression-free survival (PFS) by treatment arm for the intent-to-treat 
population (N=266). PFS was defined as the time from the date of randomization to the 
first date of progressive disease (PD), which was identified by MRI, evidence of 
neurologic progression, or death. 
Figure 2b. Overall survival (OS) by treatment arm for the intent-to-treat population 
(N=266). OS was defined as the time from the date of randomization to death. Time-to-
event estimates were calculated using the Kaplan-Meier method and were compared 
between regimens using the log-rank test. 
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Enzastaurin 
n=174 
Lomustine 
n=92 
Enzastaurin 
n=167 
Lomustine 
n=84 
Discontinued after 
randomization, n=8  
Enrolled 
n=266 
Entry criteria not met, n=27 
Entered 
N=293 
Discontinued after 
randomization, n=7  
Reasons for discontinuation: Enzastaurin Lomustine 
Progression of disease 134 66 
Adverse event    12   4 
Death    11   4 
Other*   10 10 
 
2:1 randomization 
*Includes: protocol violation, entry criteria not met, lost to follow-up, physician or patient decision, 
unknown. 
Still on-study, n=3 Still on-study, n=0 
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HR (95% CI): 1.28 (0.97, 1.70) 
Log-rank P=0.08 
Time (months) 
  18.95 (10.10, 27.80) 1.64 (1.48, 2.79) Lomustine 
11.07 (6.16, 15.98) 1.51 (1.45, 2.10) Enzastaurin 
6-month rate, % (CI)  Median PFS, mos (CI)   
1.0 
0.9 
0.8 
0.7 
0.6 
0.5 
0.4 
0.3 
0.2 
0.1 
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  Median OS (CI), months 
Enzastaurin 6.60 (5.22, 7.75) 
Lomustine 7.13 (6.01, 8.80) 
HR (95% CI): 1.20 (0.88, 1.65)
  Log-rank P=0.25 
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